iiinova — where your digital self keeps evolving

Redenlab Inc. @redenlab.bsky.social · 20/09/2026

What happens when the way someone speaks in the clinic isn’t the way they speak in everyday life? A new review led by John Dean, Lena O’Flynn & Julie Barkmeier-Kraemer explores how breathing, eating & talking can be underrecognised in movement disorders. 🧪🧠📈 redenlab.com/publication/...

010

Redenlab Inc. @redenlab.bsky.social · 09/09/2026

Can NLP tools categorise word types across languages? In paper led by @lottiegasp.bsky.social, 105 linguists tagged parts of speech across 52 language varieties. Results varied significantly, showing why multilingual methods matter in clinical language analysis. 🧪🧠📈 redenlab.com/publication/...

Can NLP tools categorise different word types across languages? A noun. A verb. An adjective.

We tested NLP tools across 52 languages.

105 linguists from 42 countries annotated a translated language passage for its word types.

We tested how well NLP tools could categorise word types compared to the linguists’ decisions.

Key findings:
- NLP tools for 25 languages had strong performance. Next, longer samples need to be tested.
- The remaining languages had unclear or weak NLP tools. We recommend ways to improve performance.
- We've openly shared our methodology, data, and code so the research community can undertake these next steps.

Published in Natural Language Processing Journal. Author affiliations include Redenlab, UniMelb, Murdoch Children's Research Institute and more.

030

Redenlab Inc. @redenlab.bsky.social · 02/09/2026

We're hiring Director of Clinical Operations in US! If you're passionate about delivering operational success, leading innovative teams and actually seeing the impact of your work, this one's for you. Apply or learn more: lnkd.in/gRM_9jqH Know someone who'd be perfect? Share this with them!

Redenlab is hiring Director of Clinical Operations

000

Redenlab Inc. @redenlab.bsky.social · 13/08/2026

Can AI detect Alzheimer's before you notice anything's wrong? Our new review (45 studies) explores machine learning based speech analysis as a digital biomarker for prescreening early AD and MCI, alongside monitoring. Promising, but needs stronger validation. 🧪🧠📈 redenlab.com/publication/...

130

Redenlab Inc. @redenlab.bsky.social · 28/07/2026

Why do we cry out in pain? Can that sound be measured? Our study with UniMelb on speech and pain (published in PAIN Reports) just got featured in La Presse's science column. Vocal biomarkers are moving pain assessment from subjective to objective. 📰 www.lapresse.ca/actualites/s... 🧪🧠📈

Publication highlights: What can speech tell us about pain?

Key findings:
- Speech can serve as a marker of acute pain.
- Speech was pain sensitive.
- Under acute pain: Syllabic rate & speech-to-pause ratio increased during monologue task. Mean sound pressure level decreased during vowel production.
- Producing a monologue reduced pain more than saying /a:/.

Published in PAIN Reports. In partnership with University of Melbourne.

031

Redenlab Inc. @redenlab.bsky.social · 09/07/2026

Speech changes can appear years before a Parkinson's disease diagnosis. A new review led by Fangyuan Cao explores the potential of speech and language as biomarkers, with contributions from our CEO Prof Adam Vogel. 🧪🧠📈 Read more: redenlab.com/publication/...

042

Redenlab Inc. @redenlab.bsky.social · 30/06/2026

Research by Dr Thayabaran Kathiresan, Dr Loretta Gasparini and Dr Alveena Siddiqui will be presented by our CEO Prof Adam Vogel at #AAIC26. Three posters spanning speech AI, multilingual NLP and biomarkers. If you're attending, come say hi! 👋

See you at Alzheimer's Association International Conference at 13-14 July, London.

With Prof Adam Vogel, CEO of Redenlab.

011

Redenlab Inc. @redenlab.bsky.social · 29/06/2026

Not all speech AI performs the same and it matters. Our CEO Prof Adam Vogel will present Dr Thayabaran Kathiresan's research at the International Conference on Primary Progressive Aphasia in London this July. Come say hi! 👋 @icppa.bsky.social 🧪🧠📈 Info: www.speechtherapyppa.com/icppa-confer...

See you at International Conference on Primary Progressive Aphasia. Happening 16 - 17 July at University College of London.

Redenlab's CEO Professor Adam Vogel will be presenting "Not all ASR is equal: a multimetric comparison of automatic speech recognition systems for dementia speech".

031

Redenlab Inc. @redenlab.bsky.social · 21/06/2026

Imagine losing your voice rapidly. That's motor neurone disease (MND), aka ALS. Today is Global MND Awareness Day. At Redenlab, we measure speech changes early and accurately, because every trial deserves the science to back it up. For everyone living with MND. For everyone who loves them. 🧪🧠📈

21st June is Global MND Awareness Day. MND robs people of their voice. We're working to track every change.

1 in 300 people will develop MND in their lifetime. No cure and few effective treatments exist today.

Our focus.

Speech is one of the first things MND takes. Objective, early measurement of changes is key.

We measure speech biomarkers that detect subtle changes, before they become visible on standard assessments.

We partner pharma and international consortia to strengthen evidence for tracking treatment response in ALS/MND.

Our ALS/MND Work: putting science behind the standard of care.

- Published scoping review on speech treatment for dysarthria in ALS.
- Validating speech as a trial endpoint with global pharma & opnion leaders.
- Advancing protocols for decentralised trials, no clinic visit is required.

Every voice matters. Our MND community deserves better tools and faster answers.

0123

Redenlab Inc. @redenlab.bsky.social · 16/06/2026

What if you could spot a child's language disorder before it fully emerges? Meet @lottiegasp.bsky.social, clinical linguist and researcher at Redenlab. Swipe through to see her work. 🧪🧠📈 Read more: 🔬 doi.org/10.1111/jcpp... 🧬 doi.org/10.1016/j.ps... 📄 doi.org/10.1111/1460...

072

Redenlab Inc. @redenlab.bsky.social · 25/05/2026

Cardiometabolism, neuroscience, sleep, immunology, regulatory. The Digital Biomarkers in Clinical Trials Summit gathers people moving the needle on how we measure what matters in clinical research. We'll be there with our partner PanAgora Pharma. 🧪🧠📈More info: digitalbiomarkers.panagorapharma.com

See you at 9th Annual Digital Biomarkers in Clinical Trials Summit on 23 June at Basel.

With Redenlab's CEO - Prof Adam Vogel, Chief Medical Officer - Dr Gustavo Noffs, and Director of Clinical Projects - Lisa Graf.

130

Redenlab Inc. @redenlab.bsky.social · 19/05/2026

What if a person's voice could tell you their brain is changing, before any test confirms it? That's the question our CEO Prof Adam Vogel will be exploring. Reduced speech complexity, subtle shifts in rhythm, slower rate aren't random. They're signals. 🧪🧠📈 More info: agedcare.salusevents.org/acqs

See you at National Aged Care Convention 2026.

Prof Adam Vogel (CEO of Redenlab) will be presenting "Early speech changes as clinical clues for cognitive decline" on 21 May 2026, 1:50PM at Royal Randwick Racecourse, Sydney.

061

Redenlab Inc. @redenlab.bsky.social · 24/04/2026

In clinical research, quality isn’t optional, it’s expected. Rupali Kumar leads quality assurance at @redenlab.bsky.social, working across audits, compliance & continuous improvement. Her focus is simple: Keeping our systems robust, reliable & always ready for the standards our partners depend on.

Photo of Rupali, Redenlab's Quality Assurance Manager, on the right. A quote from her on the left hand side: "I take pride in strengthening Redenlab’s foundation in quality, compliance, and continuous improvement."

We asked Rupali: "What shaped your journey?"

She answered: " My career has been shaped by experience in quality assurance, compliance, and regulated processes across clinical research, healthcare, and software environments.

Through working in audits, validation, training, document control, and continuous improvement, I have grown into my current role as Quality Assurance Manager at Redenlab."

We asked her: "What does your role focus on?"

She replied: "I continue to support quality and continuous improvement across the organisation.

It has been a valuable experience to work through complex customer audits and collaborate with diverse teams across the business, supporting both people and quality outcomes."

We asked her: "What makes the work meaningful?"

She replied: " Every day at Redenlab gives me the opportunity to challenge myself, learn something new, and continue growing.

It is truly a privilege to support Redenlab in its journey of growth and expansion."

130

Redenlab Inc. @redenlab.bsky.social · 19/03/2026

Deepfake voice and fraud are still on the rise. Is your security ready to keep up? Join to hear from Dr Thayabaran Kathiresan, our Senior Director of Speech Science, on detecting these threats and strengthening voice authentication with layered defences. 🔗 www.clutchevents.co/events/sydne...

000

Redenlab Inc. @redenlab.bsky.social · 10/02/2026

Losing the ability to speak is one of the most devastating consequences of ALS. A new paper led by Dr Brooke-Mai Whelan reviews decades of research on speech treatment for ALS and finds limited evidence and little clinical guidance. 🧪🧠📈 redenlab.com/to-treat-or-... #bskySPEECHIES

020

Redenlab Inc. @redenlab.bsky.social · 18/12/2025

2025 at Redenlab was shaped by collaboration. From researchers and clinicians to participants around the world, thank you for helping turn everyday speech into meaningful insight. Here’s a look at what we built together this year. #bskySPEECHIES

010

Redenlab Inc. @redenlab.bsky.social · 26/11/2025

Rodent studies are essential, yet many assays don’t reflect human disease. Motor & behavioural changes help, but mice also communicate ultrasonically - signals we can’t hear. Adam will share how these patterns can better link preclinical models to human speech at SGV. 🧪 sgv.org/en/uuid/i/78...

012

Redenlab Inc. @redenlab.bsky.social · 26/11/2025

Prof Angela Morgan led team calling to better differentiate speech vs language in genetics. Clearer terms = better diagnosis & care. With input from Prof Adam Vogel, our CSO, advancing communication science. In @ejhg-journal.bsky.social 🧪🧠📈 www.nature.com/articles/s41... #bskySPEECHIES

Publication highlights of the paper "Speech and language classification in the human phenotype ontology (HPO)". The right hand side features a photo of children undergoing speech therapy.

Key findings:
Speech & language difficulties often co-occur, but are distinct abilities.
- Speech: perception & motor production of sounds
- Language: understanding & producing messages (spoken/written)

Current classification systems (e.g. HPO) has overlapping and inconsistent speech & language categories.

Key findings:
Researchers proposed a simplified and revised classification framework that distinctly separates speech & language domains and their subtypes.

This framework will improve:
- Precision in diagnosis & phenotyping
- Targeted therapies for neurogenetic communcation disorders
- Data-driven discovery from medical records worldwide

To read full paper, check out link in caption.

Paper is published in European Journal of Human Genetics.

Author affiliations include Berlin Institute of Health, Murdoch Children's Research Institute, University of Melbourne, The Jackson Laboratory and University of Sheffield.

093

Redenlab Inc. @redenlab.bsky.social · 15/10/2025

Lottie from our team helped create fun language tasks in the GenV & Me app. Families across Victoria can explore how their 4-years-old use language. By recording and analysing these, we can spot early signs of language difficulties and help families get support sooner. #bskySPEECHIES 🧪

030

Redenlab Inc. @redenlab.bsky.social · 08/10/2025

Struggling to follow conversations in noisy places could be a neurological condition. New study w/ Monash, @unimelb.bsky.social, @unituebingen.bsky.social shows speech-in-noise tests may detect early cognitive changes before symptoms appear in Huntington’s disease. 🧪🧠📈 redenlab.com/examination-...

Cover page with title: Publication Highlights
"Examination of speech processing in noise reveals cognitive deficits in early Huntington's disease (HD)"

Key findings include:
Speech-in-noise processing reveals cognitive changes in Huntington's disease, even before symptoms appear.
Manifest HD: most impaired, particularly with multi-talker babble that strains executive function and working memory.
Premanifest HD: subtle but measurable deficits, especially when recalling single words without context.

Multi-talker noise hits hardest, reflecting working memory and attention challenges.

Speech-in-noise task predicted disease status with high sensitivity and specificity - a promising remote, non-invasive screening tool.

Everyday impact: Reducing background voices and using spatial cues can help people with HD communicate more easily

To read the full paper, check out link in caption.

Published in Cortex (with journal cover image attached).
Partners include Monash University, University of Melbourne, University of Tübingen.

1153

Redenlab Inc. @redenlab.bsky.social · 14/08/2025

Prof Angela Morgan’s research, featured in ZME Science, found the first direct link between a rare PPID gene mutation and brain structure differences in people who stutter. We’re grateful to have supported speech data collection. 🧪🧠📈 www.zmescience.com/science/news... #bskySPEECHIES

zmescience.com

Stuttering Has Deep Genetic Roots and May Affect Your Ability to Clap to a Beat

A massive genetic study found that stuttering is not just about nurture and may link to processing rhythm itself.

03511

Redenlab Inc. @redenlab.bsky.social · 25/07/2025

‪New trial shows triheptanoin may treat rare neurodegenerative disease A-T & flags biomarkers to track. Thanks to UQ, @griffith.edu.au & more. Now in @ebiomedicine.bsky.social 🧪 redenlab.com/phase-2a-b-randomised-placebo-controlled-dose-escalation-trial-of-triheptanoin-for-ataxia-telangiectasia/

Publication highlights: Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.

Key findings include:
1. Improved mitochondrial function was observed in patients with A-T treated with triheptanoin

2. Statistically significant and clinically meaningful improvements reported during the trial

3. Neurofilament light chain and interferon gene signature identified as promising biomarkers for monitoring disease progression and treatment response

4. Findings build on in vitro evidence showing that mitochondrial dysfunction in A-T cells is reversible and preventable with triheptanoin

5. Supports the potential of triheptanoin as a disease-modifying therapy for A-T

To read the full paper, check out link in caption.

Published in eBioMedicine.

Partners include: Queensland Children's Hospital, Wesley Medical Research, University of Queensland, Griffith University, Australian Institute for Bioengineering and Nanotechnology, University of Melbourne, CSIRO Australian e-Health Research Centre, University of New South Wales, John Hunter Children's Hospital, Royal Brisbane and Women's Hospital, Garvan Institute of Medical Research, QIMR-Berghofer Research Institute.

By Redenlab.

090

Redenlab Inc. @redenlab.bsky.social · 21/07/2025

Just 10s saying “pa ta ka” can reveal early #Alzheimer’s risk. Our new study at @geroscience.bsky.social shows speech changes predict memory, thinking skills pre-diagnosis. Thanks to partners @wickingdementia.bsky.social, @utas.edu.au, UniMelb, Royal Hobart Hosp. 🔗: redenlab.com/rapid-repeti...

New publication by Redenlab: rapid repetitive syllable sounds associate with episodic memory, executive function, and working memory in cognitively healthy and subjectively impaired older adults.

Key findings include:
10-second “pa,” “ta,” “ka” speech test predicts cognitive function in older adults.

“Pa” test best linked to memory, executive function, and working memory.

Speech features add predictive power beyond age, education and mood.

Stronger executive function links in healthy adults; episodic memory links in those with cognitive concerns.

Speech-to-pause ratio and syllable timing were key markers.

The study supports remote, non-invasive early screening for Alzheimer’s risk.

To read full paper, check out link in post.

The study is published in GeroScience journal.

Partners include: University of Melbourne, University of Tasmania, Royal Hobart Hopsital.

2114

Redenlab Inc. @redenlab.bsky.social · 15/05/2025

Proud to contribute to a roadmap for advancing digital health tools in frontotemporal degeneration. Speech & language are key markers and our tech is helping lead the way. For more info: redenlab.com/redenlab-con...

100